DIT

AMCON is a thin-margin convenience-store wholesaler (6.7% gross margin, the structural ceiling of cigarette/tobacco distribution) where the story is a steady erosion of earnings against a growing topline. Revenue rose to $2.82B (+3.9%), but the growth is acquisition- and price-driven — the MD&A attributes the gain to $120.8M from the Burklund/Richmond Master deals, $23.2M from Arrowrock, and $115.2M of cigarette-manufacturer price increases, all partially offset by a $176.3M decline in cigarette-carton volume. That last figure is the heart of the problem: the core category is in secular volume decline, and the company is taxed on it twice — by the FDA's evaluation of menthol/cigarette/vape prohibitions (flagged in Risk Factors) and by multi-year cost inflation in labor, benefits, equipment and insurance. SG&A climbed to 5.9% of sales from 5.7%, and with gross margin pinned at 6.7%, that 20bp creep was enough to drop operating income 30% to $12.6M and net income to just $569K. The earnings trajectory is unambiguous: $16.7M (FY22) → $11.6M → $4.34M → $0.57M. Diluted EPS fell 87% to $0.92, so the headline 79x P/E is meaningless trough math, not a growth multiple.

What keeps this off the sell list is the balance sheet and the price. Stockholders' equity is $113M against a market cap of just $47.4M — the stock trades at roughly 0.4x book ($72.79 vs. ~$174 book value per 651K shares). Leverage is light (≈$16.5M total debt vs. $113M equity), working capital is solid (current assets $240M vs. $112M current liabilities), and operating cash flow, though down sharply, was still positive at $18.7M — comfortably covering $9.0M capex and the $645K dividend. This is a discounted, asset-supported micro-cap, not a distressed one.